Table 1.
Annual Characteristics of Participants in the IPEC Women’s HIV Cervical HPV Genotyping Study at Time of Cervical Specimen Collection (2006-2012)
| 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | ||
|---|---|---|---|---|---|---|---|---|
|
|
||||||||
| N = 590 | 102 | 167 | 240 | 282 | 256 | 260 | 225 | |
|
|
||||||||
| First Appointment a |
75 (74%) | 55 (33%) | 69 (29%) | 105 (37%) | 71 (28%) | 59 (23%) | 66 (29%) | |
|
| ||||||||
| Age | ||||||||
|
| ||||||||
| Median (IQR) | 35.5 (29.3 - 42.0) | 36.0 (30.0 - 43.0) | 37.0 (30.8 - 44.3) | 36.5 (31.0 - 45.8) | 38.0 (31.0 - 46.0) | 38.0 (31.0 - 46.0) | 40.0 (32.0 - 47.0) | |
| <30 | 26 (25%) | 40 (24%) | 53 (22%) | 60 (21%) | 51 (20%) | 56 (22%) | 39 (17%) | |
| 30 - 39 | 41 (40%) | 61 (37%) | 88 (37%) | 110 (39%) | 86 (34%) | 84 (32%) | 71 (32%) | |
| 40 - 49 | 28 (27%) | 51 (31%) | 72 (30%) | 74 (26%) | 80 (31%) | 77 (30%) | 74 (33%) | |
| ≥50 | 7 (7%) | 15 (9%) | 27 (11%) | 38 (13%) | 39 (15%) | 42 (16%) | 41 (18%) | |
| Unknown | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (<1%) | 0 (0%) | |
| Current CD4 Count (cells/mm3) | ||||||||
|
| ||||||||
| >350 | 55 (54%) | 96 (57%) | 156 (65%) | 201 (71%) | 178 (70%) | 193 (74%) | 172 (77%) | |
| ≤350 | 31 (30%) | 58 (35%) | 71 (30%) | 59 (21%) | 56 (22%) | 46 (18%) | 40 (18%) | |
| Unknown | 16 (16%) | 13 (8%) | 13 (5%) | 22 (8%) | 22 (8%) | 21 (8%) | 13 (5%) | |
| Current HIV Viral Load (copies/mL)b | ||||||||
|
| ||||||||
| Detectable | 45 (44%) | 79 (47%) | 98 (41%) | 106 (38%) | 79 (31%) | 103 (40%) | 83 (37%) | |
| Undetectable | 35 (34%) | 60 (36%) | 121 (50%) | 136 (48%) | 146 (57%) | 129 (50%) | 125 (56%) | |
| Unknown | 22 (22%) | 28 (17%) | 21 (9%) | 40 (14%) | 31 (12%) | 28 (10%) | 17 (7%) | |
| Cervical Cytology | ||||||||
|
| ||||||||
| Negative | 77 (75%) | 130 (78%) | 190 (79%) | 200 (71%) | 193 (75%) | 187 (72%) | 179 (80%) | |
| ASC-US | 10 (10%) | 12 (7%) | 26 (11%) | 29 (10%) | 24 (9%) | 28 (10%) | 21 (9%) | |
| AGC | 0 (0%) | 1 (<1%) | 0 (0%) | 0 (0%) | 1 (<1%) | 2 (1%) | 0 (0%) | |
| ASC-H | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | |
| LSIL | 15 (15%) | 18 (11%) | 21 (9%) | 42 (15%) | 34 (13%) | 33 (13%) | 23 (10%) | |
| HSIL | 0 (0%) | 4 (2%) | 2 (<1%) | 8 (3%) | 2 (1%) | 7 (3%) | 1 (<1%) | |
| Cervical Cancer | 0 (0%) | 0 (0%) | 1 (<1%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | |
| Unknown | 0 (0%) | 2 (1%) | 0 (0%) | 3 (1%) | 2 (1%) | 3 (1%) | 1 (<1%) | |
| Cervical Treatment | ||||||||
|
| ||||||||
| Hysterectomy | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (<1%) | |
| Cone | 1 (1%) | 1 (<1%) | 2 (<1%) | 3 (1%) | 3 (1%) | 4 (2%) | 3 (1%) | |
| Cauterization | 0 (0%) | 0 (0%) | 0 (0%) | 4 (1%) | 6 (2%) | 5 (2%) | 4 (2%) | |
| LEEP | 4 (4%) | 4 (2%) | 5 (2%) | 2 (<1%) | 1 (<1%) | 2 (1%) | 0 (0%) | |
| Any HPV | ||||||||
|
| ||||||||
| ≥One HPV | 72 (71%) | 88 (53%) | 135 (56%) | 170 (60%) | 180 (70%) | 187 (72%) | 159 (71%) | |
| No HPV | 30 (29%) | 79 (47%) | 105 (44%) | 112 (40%) | 76 (30%) | 73 (28%) | 66 (29%) | |
| HR-HPV Genotype Prevalence (%) | ||||||||
|
| ||||||||
| 16 | 25 | 13 | 10 | 12 | 12 | 15 | 12 | |
| 18 | 12 | 13 | 7 | 6 | 11 | 7 | 8 | |
| 31 | 11 | 7 | 3 | 7 | 8 | 9 | 12 | |
| 33 | 1 | 7 | 5 | 5 | 6 | 4 | 3 | |
| 35 | 6 | 7 | 9 | 9 | 11 | 13 | 13 | |
| 39 | 10 | 3 | 4 | 6 | 7 | 7 | 12 | |
| 45 | 4 | 6 | 5 | 7 | 5 | 4 | 10 | |
| 51 | 7 | 5 | 5 | 8 | 13 | 15 | 7 | |
| 52 | 6 | 7 | 9 | 6 | 6 | 8 | 6 | |
| 56 | 10 | 7 | 4 | 5 | 5 | 5 | 11 | |
| 58 | 25 | 13 | 12 | 19 | 20 | 26 | 21 | |
| 59 | 2 | 7 | 8 | 7 | 11 | 19 | 24 | |
| 68 | 24 | 8 | 5 | 5 | 8 | 9 | 10 | |
| 73 | 0 | 4 | 5 | 4 | 5 | 3 | 7 | |
| 82 | 1 | 2 | 2 | 1 | 3 | 2 | 5 | |
a
90 of the 590 women had their first appointment in 2005
b
Detectable defined as ≥400 copies/mL from 2006 - 2010, and ≥50 copies/mL from 2011 - 2012, based on assays used